AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Northcape Capital’s Fleur Wright may have missed out in the early AI and GLP-1 investor frenzy, but she made other good calls ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

During a recent subcommittee hearing, Sanders called out Novo Nordisk’s CEO and demanded that Americans be treated fairly. "All we are saying, Mr. Jørgensen, is treat the American people the same way ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

We recently published a list of Jim Cramer’s Latest Portfolio: Top 9 Stocks to Buy and Sell. Since Pfizer Inc. (NYSE:PFE) ...

The number of Australians taking weight-loss drugs is growing as new medicines hit the market. MPs warn the influx must be ...

The private equity consortium set to take over Hargreaves Lansdown has added more lenders to the group financing the £5.4bn ...

Novo Nordisk who makes the drug said “Patient safety is a top priority,” in a statement shared with NewsNation’s The Hill. For the latest news, weather, sports, and streaming video, head to NewsNation ...

One of the current stars of the biotech world is Viking Therapeutics (NASDAQ: VKTX), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if ...

Financial analysis of Dell stock reveals shrinking backlog, revenue declines in AI-servers, and increased competition ...

Experts Amanda Kuit and Tim Noakes criticize the off-label use of Ozempic for weight loss, arguing it promotes a quick-fix ...